Skip to main content
. 2021 Apr 9;22(3):126. doi: 10.1208/s12249-021-01974-3

Fig. 1.

Fig. 1

Expected long-term storage temperatures and shelf-lives of various COVID-19 vaccine candidates in Phase 3 or Phase 2/3 clinical trials. Thermostable vaccines can be developed via the inclusion of thermostabilizing technology or the transformation of liquid vaccines into dry powders